EIKEN 免疫捕獲肺炎鏈球菌檢測試劑盒

廣州健侖生物科技有限公司

主要用途：用于檢測尿標(biāo)本中的肺炎鏈球菌抗原，以支持肺炎鏈球菌感染的診斷。

產(chǎn)品規(guī)格：20T/盒

存儲條件：2-30℃

EIKEN 免疫捕獲肺炎鏈球菌檢測試劑盒

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無形體、蜱蟲、恙蟲、利什曼原蟲、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

【產(chǎn)品介紹】

EIKEN

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-3室
【企業(yè)文化】

研究人員說，重要的是，本文提供了一種機(jī)制，可能解釋人類癌癥中的基因形式如何變化。因而，這將對于今后確定BIR是否能夠?qū)е禄鶊F(tuán)簇突變形成的研究很重要。如果這被證明是真實(shí)的，這可能對與開發(fā)癌癥的治療方法產(chǎn)生一個新的靶標(biāo)。
多形性膠質(zhì)母細(xì)胞瘤或GBM是成年人中的zui常見且具有侵襲性的腦腫瘤。多年來，該腫瘤細(xì)胞被認(rèn)為局限于腦部，但由Carolin Müller 及其同事所做的一項(xiàng)新的研究發(fā)現(xiàn)，高達(dá)20%的GBM患者在其血液中也有循環(huán)腫瘤細(xì)胞。這一發(fā)現(xiàn)可解釋為什么那些從罹患GBM者那里接受抗原抗體的人會在移植后在腦部以外出現(xiàn)腫瘤。而它可能表明是GBM患者在成為器官捐贈者之前進(jìn)行篩檢的一種方法。
Müller 及其同事發(fā)現(xiàn)，從GBM患者血液中所取樣的循環(huán)腫瘤細(xì)胞要比在這些病人中預(yù)計(jì)發(fā)現(xiàn)的顱外腫瘤數(shù)多得多。他們沒有發(fā)現(xiàn)對顱腦腫瘤動手術(shù)會增加腫瘤細(xì)胞在其它地方循環(huán)的任何證據(jù)。
在一篇相關(guān)的《焦點(diǎn)》文章中，Lara Perryman和Janine Erler提出，對GBM患者血液做循環(huán)腫瘤細(xì)胞篩檢可幫助確定哪些病人可能成為合適的器官捐贈者。他們提示，這些循環(huán)細(xì)胞還可被用作一種監(jiān)測該腦腫瘤進(jìn)展與治療的新方法。
多數(shù)細(xì)胞不能分裂，除非有足夠的氧氣存在以支持它們的后代，但是某些癌細(xì)胞和其他細(xì)胞類型規(guī)避了這個規(guī)則?，F(xiàn)在，美國約翰霍普金斯大學(xué)的研究人員鑒定出廢除細(xì)胞警告信號的機(jī)制，使得癌細(xì)胞能夠繼續(xù)分裂即使在沒有強(qiáng)大的血液供給條件下。在這個過程中，研究人員發(fā)現(xiàn)溶酶體——細(xì)胞的蛋白質(zhì)‘重復(fù)利用中心’——幫助控制細(xì)胞分裂的決定。他們還發(fā)現(xiàn)了新的證據(jù)表明某些藥物能夠停止腫瘤的生長，具有高水平的蛋白HIF-1α。

Importantly, the researchers say that this article provides a mechanism that might explain how the genetic form in human cancers changes. Thus, this will be important for future studies to determine whether BIR can result in the formation of cluster mutations. If this proves to be true, this may create a new target for the development of cancer therapies.
Glioblastoma multiforme or GBM is the most common and aggressive brain tumor in adults. For years, the tumor cells were thought to be confined to the brain, but a new study by Carolin Müller and colleagues found that as many as 20% of GBM patients have circulating tumor cells in their blood. This finding explains why people who receive antigen antibodies from people with GBM develop tumors outside the brain after transplantation. And it may indicate a way for GBM patients to screen before they become organ donors.
Müller and colleagues found that circulating tumor cells sampled from the blood of GBM patients were much more numerous than the extracranial tumors expected to be found in these patients. They found no evidence that cranial brain surgery would increase the circulation of tumor cells elsewhere.
In a related Focus article, Lara Perryman and Janine Erler suggest that circulating tumor cell screening of GBM patients' blood can help determine which patients may be suitable organ donors. They suggest that these circulating cells may also be used as a new method of monitoring the progress and treatment of this brain tumor.
Most cells can not divide unless certain oxygen is present to support their offspring, but some cancers and other cell types circumvent this rule. Now, researchers at Johns Hopkins University in the United States have identified a mechanism to abolish cellular warning signals so that cancer cells can continue dividing even without a strong blood supply. In the process, researchers found that lysosomes - the cellular protein 'recycle center' - helped to control cell division. They also found new evidence that certain drugs stop tumor growth and have high levels of protein HIF-1α.